Pomalidomide

Drug Profile

Pomalidomide

Alternative Names: Actimid; CC-4047; CDC-394; Imnovid; Pomalidomide-Celgene; Pomalyst

Latest Information Update: 07 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Celgene Corporation
  • Developer Celgene Corporation; Dana-Farber Cancer Institute; Sarah Cannon Research Institute; University of Texas M. D. Anderson Cancer Center
  • Class Anti-inflammatories; Antineoplastics; Phthalimides; Piperidones; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Cytokine modulators; Interleukin 6 inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelofibrosis; Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple myeloma
  • Phase II Brain cancer; Systemic scleroderma
  • Phase I/II Amyloid light-chain amyloidosis
  • Phase I Waldenstrom's macroglobulinaemia
  • No development reported Myelofibrosis; Pancreatic cancer; Sickle cell anaemia; Small cell lung cancer

Most Recent Events

  • 14 Sep 2017 Oncolytics Biotech, Celgene Corporation and University of Leeds initiate enrolment in the phase I MUK eleven trial in Multiple myeloma (Combination therapy, Second-line therapy or greater) in United Kingdom (IV) (ISRCTN14749537)
  • 22 Aug 2017 Phase-II clinical trials in Brain cancer (Monotherapy, Recurrent, Second-line therapy or greater, In adults, In adolescents, In children, In infants, In the elderly) in France, Spain, USA (PO) (NCT03257631) (EudraCT2016-002903-25)
  • 03 Aug 2017 Celgene plans a phase II trial for Brain cancer (Monotherapy, Recurrent, Second-line therapy or greater, In adults, In adolescents, In children, In infants, In the elderly) in France, Italy, Spain, United Kingdom and USA (EudraCT2016-002903-25) (NCT03257631)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top